According to a new market report published by Lucintel, the future of the orthobiologic market looks promising with opportunities in the osteoarthritis and degenerative arthritis, spinal fusion, fracture recovery, soft tissue injuries, and maxillofacial & dental applications. The global orthobiologic market is expected to grow with a CAGR of 8% from 2020 to 2025. The major drivers for this market are increasing incidence of sports injuries and road accidents, rising incidence of spinal diseases/disorders, and growing geriatric and obese population.
To download report brochure, please go to https://www.lucintel.com/orthobiologic-market.aspx and click "download brochure" tab from the menu
The orthobiologics are also called regenerative cellular therapies. Products related to orthobiologics contain growth factors to facilitate tissue healing, improve pain, and help restore the normal functioning. In this market, viscosupplementation products, DBM (Demineralized Bone Matrix), synthetic orthobiologics, BMP (Bone Morphogenetic Protein), allografts, PRP (Platelet Rich Plasma), and BMAC (Bone Marrow Aspiration Concentrate) are the major products. Lucintel forecasts that viscosupplementation segment will remain the largest product segment over the forecast period due to high adoption of the procedure as it is associated with minimally invasive procedure with reduced pain and low cost.
Within this market, hospitals will remain the largest segment by end user over the forecast period due to the increasing adoption of orthobiological products in a wide range of spinal and reconstructive surgeries performed in hospitals.
North America will remain the largest region over the forecast period due to the presence of a well-established healthcare market and growing geriatic population in the region.
Bone Biologics, Medtronic Bioventus, Pioneer Surgical Technology, Smith & Nephew, Stryker, DePuy Synthes, Genzyme, Osiris Therapeutics, NuVasive, Zimmer Biomet, and Anthrex are among the major suppliers in the global orthobiologic market.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global orthobiologic market by product, application, end user, and region. Lucintel has prepared a comprehensive research report titled “Growth Opportunities in the Global Orthobiologic Market 2020-2025: Trends, Forecast, and Opportunity Analysis.” This Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global orthobiologic market by product, application, end user, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
Viscosupplementation Products
DBM (Demineralized Bone Matrix)
Synthetic Orthobiologics
BMP (Bone Morphogenetic Protein)
Allografts
PRP (Platelet Rich Plasma)
BMAC (Bone Marrow Aspiration Concentrate)
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
Osteoarthritis and Degenerative Arthritis
Spinal Fusion
Fracture Recovery
Soft Tissue Injuries
Maxillofacial and Dental Applications
By End User [Value ($ Million) shipment analysis for 2014 – 2025]:
Hospitals
Orthopedic Clinics & Ambulatory Care Centers
Research and Academic Institutes
Dental Clinics & Facilities
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
United States
Canada
Mexico
United Kingdom
Spain
Germany
France
This 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or visit us at helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision makers in a variety of industries. For further information, visit www.lucintel.com.